Credit Suisse AG Boosts Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Credit Suisse AG increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,956 shares of the company’s stock after purchasing an additional 2,246 shares during the period. Credit Suisse AG owned 0.12% of Amphastar Pharmaceuticals worth $2,173,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. grew its stake in Amphastar Pharmaceuticals by 1.1% in the third quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock valued at $200,854,000 after purchasing an additional 75,616 shares during the last quarter. Federated Hermes Inc. lifted its position in Amphastar Pharmaceuticals by 0.7% during the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock valued at $125,199,000 after purchasing an additional 23,095 shares during the period. Vanguard Group Inc. raised its stake in shares of Amphastar Pharmaceuticals by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock valued at $73,234,000 after buying an additional 45,385 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amphastar Pharmaceuticals by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,866,544 shares of the company’s stock valued at $52,301,000 after buying an additional 27,410 shares during the period. Finally, State Street Corp boosted its position in Amphastar Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 1,540,846 shares of the company’s stock worth $53,606,000 after purchasing an additional 218,895 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on AMPH. Piper Sandler raised their price target on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a research report on Wednesday, August 9th. Jefferies Financial Group assumed coverage on Amphastar Pharmaceuticals in a research note on Tuesday, July 25th. They issued a “buy” rating and a $70.00 price target for the company. Finally, StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th.

Insider Activity

In other news, EVP Yakob Liawatidewi sold 28,816 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $53.13, for a total value of $1,530,994.08. Following the completion of the transaction, the executive vice president now owns 69,669 shares of the company’s stock, valued at $3,701,513.97. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 36,868 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $50.85, for a total transaction of $1,874,737.80. Following the transaction, the chief financial officer now owns 105,603 shares of the company’s stock, valued at $5,369,912.55. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Yakob Liawatidewi sold 28,816 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $53.13, for a total value of $1,530,994.08. Following the sale, the executive vice president now directly owns 69,669 shares of the company’s stock, valued at $3,701,513.97. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,443 shares of company stock valued at $4,740,952. Company insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $54.53 on Monday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.53 and a quick ratio of 1.11. The stock’s 50 day simple moving average is $57.44 and its 200-day simple moving average is $46.57. The company has a market cap of $2.63 billion, a PE ratio of 27.96 and a beta of 0.84. Amphastar Pharmaceuticals, Inc. has a 1-year low of $26.76 and a 1-year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06. Amphastar Pharmaceuticals had a net margin of 18.85% and a return on equity of 20.12%. The firm had revenue of $145.71 million for the quarter, compared to the consensus estimate of $137.20 million. As a group, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.5 EPS for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).